
### [DOID:9500](http://purl.obolibrary.org/obo/DOID_9500)
**Label:** leukocyte disease

**Subclasses:** [DOID:0050747](http://purl.obolibrary.org/obo/DOID_0050747) (lymphoplasmacytic lymphoma), [DOID:9538](http://purl.obolibrary.org/obo/DOID_9538) (multiple myeloma), [DOID:1040](http://purl.obolibrary.org/obo/DOID_1040) (chronic lymphocytic leukemia), [DOID:350](http://purl.obolibrary.org/obo/DOID_350) (mastocytosis), 

**Corr. equiv. classes:** [Orphanet:67038](http://www.orpha.net/ORDO/Orphanet_67038), [OMIM:154800](http://purl.obolibrary.org/obo/OMIM_154800), [OMIM:610430](http://purl.obolibrary.org/obo/OMIM_610430), [Orphanet:33226](http://www.orpha.net/ORDO/Orphanet_33226), [OMIM:612558](http://purl.obolibrary.org/obo/OMIM_612558), [OMIM:612557](http://purl.obolibrary.org/obo/OMIM_612557), [OMIM:609630](http://purl.obolibrary.org/obo/OMIM_609630), [OMIM:254500](http://purl.obolibrary.org/obo/OMIM_254500), [OMIM:612559](http://purl.obolibrary.org/obo/OMIM_612559), [OMIM:109543](http://purl.obolibrary.org/obo/OMIM_109543), [OMIM:153600](http://purl.obolibrary.org/obo/OMIM_153600), [OMIM:151400](http://purl.obolibrary.org/obo/OMIM_151400), 

**Class expressions from DL-Learner:**

- [HP:0031047](http://purl.obolibrary.org/obo/HP_0031047) (Paraproteinemia) 62.50%
- [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) and [HP:0031047](http://purl.obolibrary.org/obo/HP_0031047) (Paraproteinemia) 62.50%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) and [HP:0031047](http://purl.obolibrary.org/obo/HP_0031047) (Paraproteinemia) 62.50%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) and [HP:0031047](http://purl.obolibrary.org/obo/HP_0031047) (Paraproteinemia) 62.50%
- [HP:0010702](http://purl.obolibrary.org/obo/HP_0010702) (Increased antibody level in blood) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 55.80%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) and [HP:0010702](http://purl.obolibrary.org/obo/HP_0010702) (Increased antibody level in blood) 55.80%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) and [HP:0010702](http://purl.obolibrary.org/obo/HP_0010702) (Increased antibody level in blood) 55.80%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 47.95%
- [HP:0001909](http://purl.obolibrary.org/obo/HP_0001909) (Leukemia) 46.82%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) 46.32%
- [HP:0010702](http://purl.obolibrary.org/obo/HP_0010702) (Increased antibody level in blood) 45.23%
- [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) 39.33%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 38.78%
- [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) 38.61%
- [HP:0005372](http://purl.obolibrary.org/obo/HP_0005372) (Abnormality of B cell physiology) 32.91%


